Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.

The Journal of investigative dermatology - 1 Aug 2021

Guhan Samantha M, Shaughnessy Michael, Rajadurai Anpuchchelvi, Taylor Michael, Kumar Raj, Ji Zhenyu, Rashid Sarem, Flaherty Keith, Tsao Hensin

Abstract excerpt

Approximately half of melanoma tumors lack a druggable target and are unresponsive to current targeted therapeutics. One proposed approach for treating these therapeutically orphaned tumors is by targeting transcriptional dependencies (oncogene starvation), whereby survival factors are depleted through inhibition of transcriptional regulators. A drug screen identified a CDK9 inhibitor (SNS-032) to have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neurofibromin 1

Share to Oxazoles

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 33745909
DOI: 10.1016/j.jid.2020.12.035
PMCID: PMC8316294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.PMID 33745909Read ↗

Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.Semantic proximity Read ↗

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.Semantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Semantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaSemantic proximity Read ↗

Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?Semantic proximity Read ↗

Specific <i>SOX10</i> enhancer elements modulate phenotype plasticity and drug resistance in melanomaSemantic proximity Read ↗

NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma.Semantic proximity Read ↗

Landscape of enhancer disruption and functional screen in melanoma cells.Semantic proximity Read ↗

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant MelanomasSemantic proximity Read ↗

Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.Semantic proximity Read ↗

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.Semantic proximity Read ↗

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.